2022 World Conference on Lung Cancer (ePosters)-EP10.01-018. Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial

Pdf Summary

The ACT4CAT study investigated the use of thromboprophylaxis in lung cancer patients. The study included 177 patients from 17 oncology departments, with 78% being male. The majority of patients were aged 65 or older and had a BMI of 30 or higher. High-risk for thrombosis agents were received by 89.3% of patients, with platinum agents being the most common. Therapeutic lines varied, with 1st line being the most common. The study found that intermediate-dose thromboprophylaxis with Low Molecular Weight Heparins (LMWHs) was both effective and safe, with a low incidence of thrombotic events and bleeding. The study concluded that LMWHs did not increase bleeding risk or interfere with anticancer treatment. Further research is needed in this area. <br /><br />It is known that malignancies can increase the risk of thrombosis, with lung cancer having an associated thrombosis rate of up to 14%. Thrombosis can also worsen the progression of lung cancer. Biomarkers and factors related to the disease and its treatment can contribute to this increased risk. The average duration of thromboprophylaxis in the study was 5.2-3.5 months, and the most commonly used antithrombotic agent was tinzaparin. It was noted that there were potential drug-drug interactions between anticancer agents and direct oral anticoagulants (DOACs). <br /><br />The ACT4CAT study was a prospective observational phase IV study conducted by the Hellenic Society for Medical Oncology (HeSMO) to record the clinical practice of thromboprophylaxis in cancer patients. The study was approved by the bioethics committee and conducted according to the Helsinki declaration. The study findings suggest that thromboprophylaxis with LMWHs using intermediate doses is a viable option for high thrombotic burden patients with active lung cancer. It highlights the importance of considering thrombosis prevention in the management of cancer patients. <br /><br />In conclusion, the ACT4CAT study found that thromboprophylaxis with LMWHs was effective and safe in lung cancer patients with a high thrombotic burden. It did not increase bleeding risk or interfere with anticancer treatment. However, further clinical research is needed in this area.

Asset Subtitle

Nikolaos G Tsoukalas

Meta Tag

Speaker Nikolaos G Tsoukalas

Topic Palliative and Supportive Care

Keywords

ACT4CAT study

thromboprophylaxis

lung cancer patients

LMWHs

thrombotic events

bleeding risk

anticancer treatment

malignancies

tinzaparin

thrombotic burden